Magnesium Carbonate
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
- Magnesium Carbonate
- Magnesium Carbonate: From Antacid Use (Original Indication Not Recorded) to Active Peptic Ulcer Disease
Magnesium Carbonate: From Antacid Use (Original Indication Not Recorded) to Active Peptic Ulcer Disease
One-Sentence Summary
Magnesium carbonate is an acid-neutralising antacid ingredient. The South African registration record does not state its original indication. The TxGNN model predicts it may be effective for active peptic ulcer disease, but there are no registered clinical trials and only 4 publications for this indication. None of the publications test magnesium carbonate on its own.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the SAHPRA licence data |
| Predicted New Indication | Active peptic ulcer disease |
| TxGNN Prediction Score | 99.96% |
| Evidence Level | L3 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known pharmacology, magnesium carbonate is an antacid that buffers gastric acid. Mechanistically, it may relieve ulcer symptoms and support healing by raising gastric pH.
Antacids were used for peptic ulcer disease before H2 blockers and proton pump inhibitors (PPIs) became standard. This is therefore largely an established antacid use, not a novel repurposing discovery. The high TxGNN score most likely reflects that known link.
Modern care (PPIs and H. pylori eradication) has largely replaced antacid-based ulcer healing. Any new role would probably be adjunctive symptom relief.
Clinical Trial Evidence
Currently no related clinical trials registered for active peptic ulcer disease.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 7034155 | 1981 | RCT | Scand J Gastroenterol | 72 patients with duodenal or prepyloric ulcer. An antacid/anticholinergic combination was compared with cimetidine and placebo. At 3 weeks, healing was 67% with cimetidine (p<0.005 vs placebo) and 50% with the antacid combination. This is not magnesium carbonate alone. |
| 6755656 | 1982 | RCT | Scand J Gastroenterol Suppl | Antacid/anticholinergic, cimetidine and placebo in active prepyloric and duodenal ulcers. No abstract is available. |
| 3003883 | 1985 | RCT | Scand J Gastroenterol | 80 patients with duodenal ulcer, all on one antacid tablet four times daily. High-fibre vs low-fibre diet gave healing of 67.5% vs 60% at 4 weeks (not significant). It tests the diet, not the antacid. |
| 35720246 | 2022 | In vitro / product evaluation | Med Pharm Rep | Laboratory evaluation of the acid-neutralising capacity of antacids marketed in Morocco. No patient outcomes. |
South Africa Market Information
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Reg. No. 45/24/0919 | Osvaren | Film-coated tablet (Fct) | Not stated in the licence data |
Essential Medicines List (EML) status is not available in the evidence pack.
The registered product is a film-coated tablet with no recorded indication. To my recollection, Osvaren is a calcium acetate/magnesium carbonate phosphate binder rather than an antacid. This should be checked against the SAHPRA Professional Information (PI). If correct, the registered product and indication differ from the antacid use in the ulcer literature.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
The drug interaction query returned no results, which is more likely missing data than proof of no interactions. Magnesium accumulation in renal impairment, and chelation-type interactions with co-administered oral drugs, should be assessed before any new use.
Conclusion and Next Steps
Decision: Hold
Rationale:
- The ulcer literature covers mixed antacid products and old comparators (cimetidine, ranitidine), so the effect of magnesium carbonate alone cannot be isolated. No clinical trials are registered.
- The SAHPRA safety data and the original indication are missing. PPIs and H. pylori eradication are now standard care.
To proceed, the following is needed:
- The SAHPRA PI (warnings, contraindications, approved indication, product composition) for Osvaren
- Confirmation of whether the registered product has any antacid use
- Mechanism of action data from DrugBank
- Trials or studies of magnesium carbonate alone, or a current-standard-of-care comparison
- A safety assessment for renal impairment and drug interactions
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.